Search for drugs:
Typing the drug name to query
INTERFERON ALFA-2B
DIR Classification
Classification:Most-DIR concern
Severity Score:4
Description in Drug Labeling: View Full Labeling: SPL in DailyMed | PDF
- WARNINGS
- Autoimmune Disorders
- Rare cases of autoimmune diseases including thrombocytopenia, vasculitis, Raynaud's phenomenon, rheumatoid arthritis, lupus erythematosus, and rhabdomyolysis have been observed in patients treated with alpha interferons, including patients treated with INTRON A. In very rare cases the event resulted in fatality. The mechanism by which these events developed and their relationship to interferon alpha therapy is not clear. Any patient developing an autoimmune disorder during treatment should be closely monitored and, if appropriate, treatment should be discontinued.
Postmarketing Surveillance
Contingency Table:
Current Drug
Other Drugs
Rhabdomyolysis
75
42837
Other ADRs
20807
14096472
Odds Ratio = 1.187
Drug Property Information
ATC Code(s):
- L03AB05 - interferon alfa-2b
- L03AB - Interferons
- L03A - IMMUNOSTIMULANTS
- L03 - IMMUNOSTIMULANTS
- L - ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
Active Ingredient:interferon alfa-2b
Active Ingredient UNII:43K1W2T1M6
Drugbank ID:DB00105
PubChem Compound:N/A
CAS Number:98530-12-2
Dosage Form(s):kit
Route(s) Of Administrator:-
Daily Dose:
Chemical Structure: 
SMILE Code:
-
-
Reference
COHORT STUDY:
N/AOTHER REFERENCE(S):
1: Acute rhabdomyolysis as a complication of interferon treatment for stage IIIc melanoma.
[Gavigan Geneviève,McEvoy Alana,Young Vince]J Cutan Med Surg.2014 Jul-Aug;18(4):277-9. PMID: 25008446
2: Acute reversible rhabdomyolysis during interferon alpha2B therapy for hepatitis C.
[Gabrielli Maurizio,Santarelli Luca,Serricchio Michele,Leo Diego,Pola Paolo,Gasbarrini Antonio]Am J Gastroenterol.2003 Apr;98(4):940. PMID: 12738487
3: Repeatable acute rhabdomyolysis with multiple organ dysfunction because of interferon alpha and dacarbazine treatment in metastatic melanoma.
[Hauschild A,Möller M,Lischner S,Christophers E]Br J Dermatol.2001 Jan;144(1):215-6. PMID: 11167727
Disclaimer:
The content of this database of rhabdomyolysis is intended for educational and scientific research purposes only. It is not intended as a substitute for professional medical advice, diagnosis or treatment.
The views presented in this website do not necessarily reflect current or future opinion or policy of the US Food and Drug Administration. Any mention of commercial products is for clarification and not intended as endorsement.